Business Context and Reporting Period
This Form 8-K was filed by Graybug Vision, Inc. (not Calcimedica, Inc.) on August 23, 2022, reporting events occurring on August 18, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Redwood City, CA. The filing details strategic actions taken following a June 28, 2022 announcement to review strategic alternatives to maximize shareholder value.
Key Financial Metrics and Restructuring Costs
The filing does not provide historical revenue, profit, cash flow, or debt metrics. It focuses exclusively on estimated future costs associated with exit and disposal activities:
- Total Restructuring Charge: Expected between $4.3 million and $5.0 million.
- Recognition Period: Quarters ending September 30, 2022, and December 31, 2022.
- Impairment and Lease Termination: $2.9 million to $3.1 million related to R&D equipment impairment and early lease termination of the Baltimore, MD facility.
- Severance and Benefits: $1.1 million to $1.2 million for approximately 20 employees (representing a ~70% workforce reduction).
- Program Wind-down Costs: $0.3 million to $0.7 million to terminate GB-102 and GB-401 clinical development programs.
Material Changes
The Company has initiated a significant contraction of its operations:
- Program Termination: All activities related to the GB-102 and GB-401 programs have been terminated.
- Workforce Reduction: A reduction in the workforce of approximately 70% is underway.
- Facility Changes: The Baltimore, Maryland facility will be vacated prior to its lease expiration on June 30, 2023.
Outlook, Risks, and Management Commentary
Management states these steps are part of a comprehensive review of strategic alternatives. The filing includes standard forward-looking statements regarding the size, timing, and impact of the workforce reduction and program terminations. The Company disclaims any obligation to update these statements and notes that actual results may differ due to inherent risks and uncertainties detailed in its Form 10-Q for the quarter ended June 30, 2022.
Investor Verification Checklist
- Verify the exact number of employees remaining post-reduction to confirm the 70% reduction figure.
- Confirm the specific lease termination terms and potential penalties for the Baltimore facility.
- Review the Company's current cash position to assess its ability to fund the $4.3M-$5.0M restructuring charge.
- Monitor subsequent filings for the actual recognition of the impairment and severance charges in Q3 and Q4 2022.
- Clarify the status of any remaining assets or intellectual property from the terminated GB-102 and GB-401 programs.